Format

Send to

Choose Destination
Curr Opin Immunol. 2015 Aug;35:9-14. doi: 10.1016/j.coi.2015.05.002. Epub 2015 May 19.

New approaches in vaccine-based immunotherapy for human papillomavirus-induced cancer.

Author information

1
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center (LUMC), 2300 RC, The Netherlands.
2
Department of Clinical Oncology, LUMC, 2300 RC, The Netherlands.
3
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center (LUMC), 2300 RC, The Netherlands; ISA Pharmaceuticals, Leiden, The Netherlands. Electronic address: C.melief@lumc.nl.

Abstract

The identification of human papillomavirus as the etiological factor for cervical cancer provides an opportunity to treat these malignancies by vaccination. Although therapeutic vaccination against viral oncogenes regularly induces a specific T cell response, clinical effectivity remains low. Three factors are particularly important for clinical outcome: the balance between cytotoxic T cells and regulatory immune subsets, the balance between cytotoxic T cells and tumor cells and finally the killing efficiency of cytotoxic T cells within the tumor. To improve these three factors, therapeutic vaccination is combined with other treatments. Here, we review those studies that are based on understanding the inhibitory mechanisms that prevent unleashing the full power of therapeutic vaccine-induced T cells and utilize combinatorial interventions based on these insights.

PMID:
26001120
DOI:
10.1016/j.coi.2015.05.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center